Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70) has announced it missed the October 28, 2026 deadline to file its annual audited financial statements for the fiscal year ended June 30, 2026, triggering a management cease trade order (MCTO) from securities regulators. The MCTO restricts trading by insiders and employees but permits continued trading in common shares by the general public. The company attributes the delay solely to its auditor requiring approximately two additional weeks to complete the audit, and anticipates filing the annual documents on or before November 15, 2026. Investors in the oral pouch and functional stimulant company may be watching closely as the company works to resolve its filing default.

Key Points

  • Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70) is a Kelowna, British Columbia-based consumer product innovation company focused on oral pouch and functional stimulant technologies.
  • The company missed the October 28, 2026 regulatory deadline to file annual audited financial statements for the fiscal year ended June 30, 2026.
  • A management cease trade order has been issued; the company targets filing completion on or before November 15, 2026.
  • Investors should watch for bi-weekly default status reports the company is required to issue under National Policy 12-203 while it remains in default.

Auditor Timeline Behind Doseology's Late Annual Filing

Doseology Sciences disclosed that the missed filing deadline is not the result of unresolved accounting matters, outstanding information requests, or any delays by management. Rather, the company states its auditor requires approximately two additional weeks to complete the audit of the annual financial statements. The company's staff is described as working diligently alongside its auditors. Doseology confirmed it is not subject to any insolvency proceedings and that there is no other material information concerning the company's affairs that has not been previously disclosed to the public.

How the Management Cease Trade Order Affects MOOD Shareholders

Under National Policy 12-203, the MCTO restricts trading in the company's securities by insiders and employees only, while permitting ordinary investors to continue buying and selling Doseology common shares on the open market. The company applied for and received this MCTO specifically to protect public shareholders from a full cease trade order that could otherwise halt all trading activity. The immediate share price impact was not clear from available public information. Investors may be watching how market sentiment responds to the disclosure of a regulatory filing default, even where public trading is permitted to continue.

Doseology's Bi-Weekly Reporting Obligations During the Default Period

While Doseology remains in default of its financial statement filing requirement, the company has committed to issuing bi-weekly default status reports as required under NP 12-203. These reports must disclose any material changes to the information provided in the initial announcement, all actions taken to remedy the default, any failures to comply with NP 12-203 provisions, and any subsequent defaults or other material information not previously disclosed. The company reiterated its intention to file all outstanding annual documents, including management's discussion and analysis and CEO/CFO certifications, on or before November 15, 2026.